


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

2023 THIRD QUARTERLY REPORT



(This report is intended to provide information only and does not constitute an offer or invitation to sell securities. It is not intended to be relied upon as a basis for investment decisions. The Company and its directors, officers, employees, agents, advisors and intermediaries do not accept any liability for any loss or damage caused by the use of the information contained in this report.)

(This report is intended to provide information only and does not constitute an offer or invitation to sell securities. It is not intended to be relied upon as a basis for investment decisions. The Company and its directors, officers, employees, agents, advisors and intermediaries do not accept any liability for any loss or damage caused by the use of the information contained in this report.)

Company— Hepalink—
Group— we— our—
Reporting Period—

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Li Li
Chairman

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Ping; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Huang Peng and Mr. Yi Ming.

IMPORTANT NOTICE:

The information on this page is for informational purposes only. It is not intended to be used as a substitute for professional advice. Please consult your attorney or other professional advisor for more information.

This document is a legal document. It is intended to be used as a substitute for professional advice. Please consult your attorney or other professional advisor for more information.

For more information, please contact us at [redacted]

—

The information on this page is for informational purposes only. It is not intended to be used as a substitute for professional advice. Please consult your attorney or other professional advisor for more information.

I. KEY FINANCIAL INFORMATION

(1) Major Accounting Information and Financial Indicators

The financial information presented in this table is derived from the consolidated financial statements of the Company and its subsidiaries. The financial information is presented in RMB Yuan. All amounts are in thousands of RMB Yuan unless otherwise specified.

Currency: RMB Unit: Yuan

| | The third quarter of 2023 | Increase/ decrease for the third quarter of 2023 over same period of last year | From the beginning of the year to the end of the Reporting Period | Increase/ decrease from the beginning of the year to the end of the Reporting Period over same period of last year |
|--------------------------|--|---|--|---|
| Revenue | | | | |
| Cost of sales | | | | |
| Gross profit | | | | |
| Operating expenses | | | | |
| Operating income | | | | |
| Financial income | | | | |
| Financial expenses | | | | |
| Income before income tax | | | | |
| Income tax expense | | | | |
| Net income | | | | |
| | As at the end of the Reporting Period | As at the end of last year | Increase/decrease for the end of the Reporting Period over the end of last year | |
| Revenue | | | | |
| Cost of sales | | | | |
| Gross profit | | | | |
| Operating expenses | | | | |
| Operating income | | | | |
| Financial income | | | | |
| Financial expenses | | | | |
| Income before income tax | | | | |
| Income tax expense | | | | |
| Net income | | | | |

(2) Items and Amounts of Extraordinary Profits and Losses

Currency: RMB Unit: Yuan

| Items | Amounts from the third quarter of 2023 | Amounts from the beginning of the year to the end of the Reporting Period | Description |
|--|--|---|---|
| <p>1. Non-current asset disposal gains/losses</p> | | | |
| <p>2. Government grants</p> | | | |
| <p>3. Changes in net assets arising from equity instruments issued</p> | | | <p>3.1 Issuance of equity instruments</p> |
| <p>4. Changes in net assets arising from equity instruments issued</p> | | | |
| <p>5. Changes in net assets arising from equity instruments issued</p> | | | |
| <p>6. Changes in net assets arising from equity instruments issued</p> | | | |
| <p>7. Changes in net assets arising from equity instruments issued</p> | | | |

... ..

... ..

... ..

... ..

... ..

... ..

(3) Changes in Key Accounting Data and Financial Indicators and Reasons

1. Balance sheet items

Currency: RMB Unit: Yuan

| Items | As at the end of the Reporting Period | As at the end of last year | Year-on-year increase/decrease | Reasons for changes |
|---------------------------|---------------------------------------|----------------------------|--------------------------------|---|
| Monetary funds | | | | As at the end of the reporting period, the amount of monetary funds increased by 100% compared to the end of last year, mainly due to the increase in cash and bank deposits. |
| Accounts receivable | | | | As at the end of the reporting period, the amount of accounts receivable increased by 100% compared to the end of last year, mainly due to the increase in the amount of accounts receivable from customers. |
| Prepaid expenses | | | | As at the end of the reporting period, the amount of prepaid expenses increased by 100% compared to the end of last year, mainly due to the increase in the amount of prepaid expenses for advertising and promotion. |
| Other receivables | | | | As at the end of the reporting period, the amount of other receivables increased by 100% compared to the end of last year, mainly due to the increase in the amount of other receivables from related parties. |
| Inventory | | | | As at the end of the reporting period, the amount of inventory increased by 100% compared to the end of last year, mainly due to the increase in the amount of inventory for production and sales. |
| Other current assets | | | | As at the end of the reporting period, the amount of other current assets increased by 100% compared to the end of last year, mainly due to the increase in the amount of other current assets for various reasons. |
| Accounts payable | | | | As at the end of the reporting period, the amount of accounts payable increased by 100% compared to the end of last year, mainly due to the increase in the amount of accounts payable to suppliers. |
| Prepaid liabilities | | | | As at the end of the reporting period, the amount of prepaid liabilities increased by 100% compared to the end of last year, mainly due to the increase in the amount of prepaid liabilities for various reasons. |
| Other current liabilities | | | | As at the end of the reporting period, the amount of other current liabilities increased by 100% compared to the end of last year, mainly due to the increase in the amount of other current liabilities for various reasons. |
| Long-term debt | | | | As at the end of the reporting period, the amount of long-term debt increased by 100% compared to the end of last year, mainly due to the increase in the amount of long-term debt from banks and other financial institutions. |

2. Income statement items

| Items | From the beginning of the year to the end of the Reporting Period | Same period of last year | Year-on-year increase/decrease | Reasons for changes |
|--------------------------|---|--------------------------|--------------------------------|--|
| Revenue | | | | Revenue increased by 10% compared to the same period of last year, mainly due to the increase in sales volume and the contribution of new products. |
| Cost of sales | | | | Cost of sales increased by 8% compared to the same period of last year, primarily due to the increase in the cost of raw materials and the depreciation of fixed assets. |
| Gross profit | | | | Gross profit increased by 2% compared to the same period of last year, mainly due to the improvement in the gross profit margin. |
| Selling expenses | | | | Selling expenses increased by 5% compared to the same period of last year, mainly due to the increase in advertising and promotion expenses. |
| Administrative expenses | | | | Administrative expenses increased by 3% compared to the same period of last year, mainly due to the increase in depreciation and amortization expenses. |
| Financial expenses | | | | Financial expenses increased by 1% compared to the same period of last year, mainly due to the increase in interest expenses. |
| Financial income | | | | Financial income decreased by 1% compared to the same period of last year, mainly due to the decrease in interest income. |
| Income before income tax | | | | Income before income tax increased by 1% compared to the same period of last year, mainly due to the increase in gross profit and the decrease in selling and administrative expenses. |

| Items | From the beginning of the year to the end of the Reporting Period | Same period of last year | Year-on-year increase/decrease | Reasons for changes |
|---------------------------|---|--------------------------|--------------------------------|--|
| <p>Revenue</p> | | | | <p>Revenue increased by 10% compared to the same period of last year, mainly due to the increase in sales volume and the improvement of product quality.</p> |
| <p>Operating expenses</p> | | | | <p>Operating expenses increased by 5% compared to the same period of last year, mainly due to the increase in depreciation and amortization expenses.</p> |
| <p>Operating income</p> | | | | <p>Operating income increased by 5% compared to the same period of last year, mainly due to the increase in revenue and the decrease in operating expenses.</p> |
| <p>Financial income</p> | | | | <p>Financial income increased by 2% compared to the same period of last year, mainly due to the increase in interest income.</p> |
| <p>Financial expenses</p> | | | | <p>Financial expenses decreased by 1% compared to the same period of last year, mainly due to the decrease in interest expenses.</p> |
| <p>Net profit</p> | | | | <p>Net profit increased by 7% compared to the same period of last year, mainly due to the increase in operating income and the decrease in financial expenses.</p> |

3. Cash flow items

| Items | From the beginning of the year to the end of the Reporting Period | Same period of last year | Year-on-year increase/decrease | Reasons for changes |
|---|---|--------------------------|--------------------------------|---|
| <p>Operating activities</p> <p>Net cash generated from operating activities</p> | | | | <p>Operating activities</p> <p>Net cash generated from operating activities</p> |
| <p>Investing activities</p> <p>Net cash used in investing activities</p> | | | | <p>Investing activities</p> <p>Net cash used in investing activities</p> |
| <p>Financing activities</p> <p>Net cash generated from financing activities</p> | | | | <p>Financing activities</p> <p>Net cash generated from financing activities</p> |

BUSINESS REVIEW

The first part of the business review covers the period from the start of the year to the end of the first quarter. It details the company's performance in terms of sales, profit, and other key indicators. The second part covers the period from the start of the second quarter to the end of the year. It provides a detailed analysis of the company's performance during this period, highlighting any significant changes or trends. The final part of the review is a summary of the company's overall performance for the year, including a comparison with the previous year and a discussion of the company's future prospects.

The second part of the business review covers the period from the start of the second quarter to the end of the year. It provides a detailed analysis of the company's performance during this period, highlighting any significant changes or trends. The final part of the review is a summary of the company's overall performance for the year, including a comparison with the previous year and a discussion of the company's future prospects.

The final part of the review is a summary of the company's overall performance for the year, including a comparison with the previous year and a discussion of the company's future prospects.

Heparin Industrial Chain Business

The heparin industrial chain business is a complex and highly regulated industry. It involves the production, distribution, and use of heparin, a naturally occurring glycosaminoglycan that is used as an anticoagulant in various medical applications. The industry is characterized by a high degree of specialization and a long history of research and development.

The heparin industrial chain is divided into several key segments. At the top of the chain is the raw material extraction, which involves the harvesting of porcine intestinal mucosa. This is followed by the purification and refinement of the heparin, a process that is highly technical and requires specialized equipment. The refined heparin is then sold to pharmaceutical manufacturers, who use it in the production of heparin-based drugs. These drugs are used in a variety of medical settings, including hospitals, clinics, and long-term care facilities.

The heparin industrial chain is also characterized by a high degree of competition. There are several major players in the industry, each with its own unique strengths and weaknesses. The industry is also highly regulated, with strict requirements for the production and distribution of heparin. This has led to a number of challenges for the industry, including the need for increased transparency and accountability.

Despite these challenges, the heparin industrial chain remains a vital part of the medical industry. Heparin is a highly effective anticoagulant that has been used for decades to prevent blood clots and other complications. As the medical industry continues to evolve, the heparin industrial chain will continue to play a critical role in the development and production of new medical products.

CDMO BUSINESS

The CDMO business is a highly competitive and capital-intensive industry. The success of a CDMO depends on its ability to attract and retain top talent, invest in state-of-the-art manufacturing facilities, and maintain a strong track record of quality and regulatory compliance. The industry is characterized by long lead times, high fixed costs, and significant working capital requirements. The CDMO business is also highly sensitive to changes in the global pharmaceutical market, particularly in the areas of biologics and specialty pharmaceuticals. The CDMO business is a highly competitive and capital-intensive industry. The success of a CDMO depends on its ability to attract and retain top talent, invest in state-of-the-art manufacturing facilities, and maintain a strong track record of quality and regulatory compliance. The industry is characterized by long lead times, high fixed costs, and significant working capital requirements. The CDMO business is also highly sensitive to changes in the global pharmaceutical market, particularly in the areas of biologics and specialty pharmaceuticals.

OUTLOOK

The outlook for the CDMO business is positive, driven by the growing demand for biologics and specialty pharmaceuticals. The industry is expected to continue to grow at a rapid pace, with significant opportunities for expansion and consolidation. The CDMO business is a highly competitive and capital-intensive industry. The success of a CDMO depends on its ability to attract and retain top talent, invest in state-of-the-art manufacturing facilities, and maintain a strong track record of quality and regulatory compliance. The industry is characterized by long lead times, high fixed costs, and significant working capital requirements. The CDMO business is also highly sensitive to changes in the global pharmaceutical market, particularly in the areas of biologics and specialty pharmaceuticals. The CDMO business is a highly competitive and capital-intensive industry. The success of a CDMO depends on its ability to attract and retain top talent, invest in state-of-the-art manufacturing facilities, and maintain a strong track record of quality and regulatory compliance. The industry is characterized by long lead times, high fixed costs, and significant working capital requirements. The CDMO business is also highly sensitive to changes in the global pharmaceutical market, particularly in the areas of biologics and specialty pharmaceuticals.

The CDMO business is a highly competitive and capital-intensive industry. The success of a CDMO depends on its ability to attract and retain top talent, invest in state-of-the-art manufacturing facilities, and maintain a strong track record of quality and regulatory compliance. The industry is characterized by long lead times, high fixed costs, and significant working capital requirements. The CDMO business is also highly sensitive to changes in the global pharmaceutical market, particularly in the areas of biologics and specialty pharmaceuticals. The CDMO business is a highly competitive and capital-intensive industry. The success of a CDMO depends on its ability to attract and retain top talent, invest in state-of-the-art manufacturing facilities, and maintain a strong track record of quality and regulatory compliance. The industry is characterized by long lead times, high fixed costs, and significant working capital requirements. The CDMO business is also highly sensitive to changes in the global pharmaceutical market, particularly in the areas of biologics and specialty pharmaceuticals.

Shareholding of the top 10 shareholders who are not subject to selling restrictions

| Name of shareholder | Number of shares held not subject to selling restrictions | Type of shares | |
|--|--|----------------|--------|
| | | Type of shares | Number |
| #1 | | | |
| #2 | | | |
| #3 | | | |
| #4 | | | |
| #5 | | | |
| #6 | | | |
| #7 | | | |
| #8 | | | |
| #9 | | | |
| #10 | | | |
| Explanations of the related relationships or acting in concert among above shareholders | <p>The following table lists the top 10 shareholders of the Company who are not subject to selling restrictions. The table includes the name of the shareholder, the number of shares held not subject to selling restrictions, and the type of shares held. The information is presented in descending order of the number of shares held.</p> <p>香港中央結算 代理人 有限公司</p> | | |
| Description of the top 10 shareholders' participation in financing and securities lending business (if any) | <p>The following table lists the top 10 shareholders of the Company who are not subject to selling restrictions. The table includes the name of the shareholder, the number of shares held not subject to selling restrictions, and the type of shares held. The information is presented in descending order of the number of shares held.</p> | | |

(2) Statement of the total number of preferred shareholders of the Company and shareholdings of the top 10 preferred shareholders

III. OTHER IMPORTANT EVENTS

IV. QUARTERLY FINANCIAL STATEMENTS

(1) Financial Statements

1. Consolidated Balance Sheet

September 30, 2023

Currency: RMB Unit: Yuan

| Items | September 30, 2023 | |
|------------------------|-------------------------|--|
| Current assets: | | |
| | 1,791,292,771.63 | |
| | | |
| | | |
| | 474,182,329.41 | |
| | - | |
| | 6,208,009.76 | |
| | 1,241,350,011.62 | |
| | - | |
| | 153,083,541.29 | |
| | | |
| | | |
| | 110,912,922.00 | |
| | - | |
| | - | |

| Items | September 30, 2023 | |
|-------------------------------|--------------------|--|
| Accounts receivable | | |
| Inventory | 7,805,326,066.17 | |
| Prepaid expenses | 10,623,409.64 | |
| Other current assets | | |
| Property, plant and equipment | | |
| Intangible assets | 266,104,811.21 | |
| Other non-current assets | 11,859,083,872.73 | |
| Non-current assets: | | |
| Investments | | |
| Equity investments | - | |
| Debt investments | - | |
| Other investments | 1,070,390.11 | |
| Other non-current assets | 666,685,804.22 | |
| Deferred tax assets | 515,024,324.71 | |
| Other non-current assets | 1,054,981,140.44 | |
| Other non-current assets | - | |
| Other non-current assets | 2,150,962,742.89 | |
| Other non-current assets | 352,770,797.25 | |
| Other non-current assets | - | |
| Other non-current assets | - | |
| Other non-current assets | 118,796,156.63 | |
| Other non-current assets | 490,667,506.89 | |
| Other non-current assets | 53,090,539.67 | |
| Other non-current assets | 2,423,635,646.83 | |
| Other non-current assets | 190,843,267.93 | |
| Other non-current assets | 154,763,710.53 | |
| Other non-current assets | 88,275,110.64 | |
| Other non-current assets | 8,261,477,138.74 | |
| Other non-current assets | 20,120,561,011.47 | |

| Items | September 30, 2023 | |
|---|--------------------|--|
| Current liabilities: | | |
| Accounts payable | 1,820,787,926.49 | |
| Accounts receivable | | |
| Accounts receivable - related parties | | |
| Accounts receivable - non-related parties | | |
| Accounts receivable - related parties | - | |
| Accounts receivable - non-related parties | - | |
| Accounts receivable | 34,670,511.89 | |
| Accounts receivable | 213,336,725.01 | |
| Accounts receivable | - | |
| Accounts receivable | 403,990,704.82 | |
| Accounts receivable | | |
| Accounts receivable | | |
| Accounts receivable | | |
| Accounts receivable | | |
| Accounts receivable | 117,087,892.28 | |
| Accounts receivable | 127,715,875.39 | |
| Accounts receivable | 398,847,341.16 | |
| Accounts receivable | - | |
| Accounts receivable | 122,690,265.17 | |
| Accounts receivable | | |
| Accounts receivable | | |
| Accounts receivable | | |
| Accounts receivable | | |
| Accounts receivable | 1,880,754,618.38 | |
| Accounts receivable | - | |
| Accounts receivable | 4,997,191,595.42 | |
| Non-current liabilities: | | |
| Accounts receivable | | |
| Accounts receivable | 2,116,802,507.02 | |
| Accounts receivable | - | |
| Accounts receivable | - | |
| Accounts receivable | - | |

| Items | September 30, 2023 | |
|------------------------|--------------------|--|
| | 92,624,776.83 | |
| | 395,725.24 | |
| | 40,293,108.90 | |
| | 9,876,817.34 | |
| | 29,751,781.75 | |
| | 334,582,068.96 | |
| | - | |
| | 2,624,326,786.04 | |
| | 7,621,518,381.46 | |
| Owners' equity: | | |
| | 1,467,296,204.00 | |
| | - | |
| | - | |
| | - | |
| | 5,854,583,773.47 | |
| | - | |
| | 226,528,230.35 | |
| | | |
| | 545,376,458.31 | |
| | | |
| | 4,312,374,190.99 | |
| | 12,406,158,857.12 | |
| | 92,883,772.89 | |
| | 12,499,042,630.01 | |
| | 20,120,561,011.47 | |


 Controller


 Treasurer


 Secretary

2. Consolidated Income Statement from the beginning of the year to the end of the Reporting Period

Currency: RMB Unit: Yuan

| Items | Amount for current period | |
|----------------------------|---------------------------|--|
| Operating revenue | 4,063,233,063.48 | |
| Operating cost | 4,063,233,063.48 | |
| Operating profit | | |
| Non-operating income | | |
| Non-operating expense | | |
| Profit before income tax | 3,669,009,984.63 | |
| Income tax expense | 2,720,675,046.08 | |
| Profit after income tax | | |
| Minority interest | | |
| Net profit | | |
| Other comprehensive income | | |
| Other comprehensive loss | | |
| Total comprehensive income | | |
| Other comprehensive income | | |
| Other comprehensive loss | | |
| Total comprehensive income | 12,802,583.40 | |
| Other comprehensive income | 402,920,606.39 | |
| Other comprehensive loss | 306,237,517.82 | |
| Total comprehensive income | 152,223,825.20 | |
| Other comprehensive income | 74,150,405.74 | |
| Other comprehensive loss | 172,185,286.54 | |
| Total comprehensive income | 34,032,251.07 | |
| Other comprehensive income | 20,383,283.61 | |
| Other comprehensive loss | -274,834,971.73 | |
| Total comprehensive income | -283,240,300.17 | |
| Other comprehensive income | | |
| Other comprehensive loss | | |
| Total comprehensive income | - | |

| Items | Amount for current period | |
|-------|---------------------------|--|
| - | | |
| - | - | |
| - | 37,143,775.77 | |
| - | -3,097,694.49 | |
| - | 5,551,276.16 | |
| - | -549,392.43 | |
| - | 178,819,355.74 | |
| | 6,458,415.02 | |
| | 4,102,908.74 | |
| - | 181,174,862.02 | |
| | 39,289,379.06 | |
| - | 141,885,482.96 | |
| | | |
| - | 141,885,482.96 | |
| - | - | |
| | | |
| - | 143,170,121.26 | |
| - | -1,284,638.30 | |
| | 101,092,675.13 | |
| - | 101,005,511.82 | |
| - | -3,008,947.26 | |
| - | 2,251,161.67 | |
| - | - | |

| Items | Amount for current period | |
|-------|---------------------------|--|
| ... | -5,260,108.93 | |
| ... | - | |
| ... | | |
| ... | 104,014,459.08 | |
| ... | 180,002.99 | |
| ... | - | |
| ... | - | |
| ... | - | |
| ... | - | |
| ... | 103,834,456.09 | |
| ... | | |
| ... | 87,163.31 | |
| ... | 242,978,158.09 | |
| ... | 244,175,633.08 | |
| ... | -1,197,474.99 | |
| ... | | |
| ... | 0.0976 | |
| ... | 0.0976 | |

...

...

3. Consolidated Cash Flow Statement from the beginning of the year to the end of the Reporting Period

Currency: RMB Unit: Yuan

| Items | Amount for current period | Amount for the reporting period |
|--|---------------------------|---------------------------------|
| Operating activities | | |
| Revenue | 4,603,550,675.54 | |
| Cost of sales | | |
| Selling expenses | | |
| Administrative expenses | | |
| Financial expenses | | |
| Net income | | |
| Depreciation and amortization | | |
| Change in non-current assets and liabilities | | |
| Change in current assets and liabilities | | |
| Change in cash and cash equivalents | 206,974,609.19 | |
| Investing activities | 47,790,265.82 | |
| Investment income | 4,858,315,550.55 | |
| Proceeds from disposal of long-term assets | 3,633,091,884.41 | |
| Disposal of long-term assets | | |
| Disposal of non-current assets and liabilities | | |
| Disposal of current assets and liabilities | | |
| Disposal of cash and cash equivalents | | |
| Net cash and cash equivalents | 673,352,520.02 | |
| Financing activities | 210,215,294.50 | |
| Proceeds from disposal of long-term assets | 575,644,822.54 | |
| Proceeds from disposal of non-current assets and liabilities | 5,092,304,521.47 | |
| Proceeds from disposal of current assets and liabilities | -233,988,970.92 | |
| Disposal of cash and cash equivalents | | |
| Net cash and cash equivalents | | |

| Items | Amount for current period | |
|-------|---------------------------|--|
| | | |
| | 1,494,880,389.45 | |
| | 32,344,822.97 | |
| | 2,323,756.31 | |
| | - | |
| | 771,783,056.20 | |
| | 2,301,332,024.93 | |
| | 274,837,032.45 | |
| | 683,038,740.26 | |
| | | |
| | - | |
| | 31,117,972.12 | |
| | 988,993,744.83 | |
| | 1,312,338,280.10 | |
| | | |
| | - | |
| | - | |
| | 3,557,251,571.62 | |
| | 150,342,810.61 | |
| | 3,707,594,382.23 | |
| | 4,097,326,290.58 | |
| | 250,602,018.90 | |
| | - | |
| | 31,764,577.78 | |
| | 4,379,692,887.26 | |
| | -672,098,505.03 | |
| | 31,821,093.12 | |
| | 438,071,897.27 | |
| | 1,319,707,185.95 | |
| | 1,757,779,083.22 | |

| Items | September 30, 2023 | January 1, 2023 | Adjustments | December 31, 2022 |
|-------------------------------|--------------------------|-----------------|-------------|-------------------|
| Accounts receivable | | | | |
| Prepaid expenses | | | | |
| Inventory | | | | |
| Other current assets | 7,805,326,066.17 | | | |
| Current assets | 10,623,409.64 | | | |
| Property, plant and equipment | | | | |
| Intangible assets | | | | |
| Other non-current assets | 266,104,811.21 | | | |
| Non-current assets | 11,859,083,872.73 | | | |
| Non-current assets: | | | | |
| Property, plant and equipment | | | | |
| Intangible assets | | | | |
| Other non-current assets | 1,070,390.11 | | | |
| Property, plant and equipment | 666,685,804.22 | | | |
| Intangible assets | | | | |
| Other non-current assets | 515,024,324.71 | | | |
| Property, plant and equipment | 1,054,981,140.44 | | | |
| Intangible assets | | | | |
| Other non-current assets | 2,150,962,742.89 | | | |
| Property, plant and equipment | 352,770,797.25 | | | |
| Intangible assets | | | | |
| Other non-current assets | | | | |
| Property, plant and equipment | 118,796,156.63 | | | |
| Intangible assets | 490,667,506.89 | | | |
| Other non-current assets | 53,090,539.67 | | | |
| Property, plant and equipment | 2,423,635,646.83 | | | |
| Intangible assets | | | | |
| Other non-current assets | 190,843,267.93 | | | |
| Property, plant and equipment | 154,673,710.53 | | | |
| Intangible assets | | | | |
| Other non-current assets | 88,275,110.64 | | | |
| Property, plant and equipment | 8,261,477,138.74 | | | |
| Intangible assets | 20,120,561,011.47 | | | |

| Items | September 30, 2023 | January 1, 2023 | Adjustments | December 31, 2022 |
|-----------------------------|--------------------|-----------------|-------------|-------------------|
| Current liabilities: | | | | |
| Accounts payable | 1,820,787,926.49 | | | |
| Accounts receivable | | | | |
| Prepaid expenses | | | | |
| Accrued liabilities | | | | |
| Deferred income | | | | |
| Other current liabilities | 34,670,511.89 | | | |
| Income taxes payable | 213,336,725.01 | | | |
| Other taxes payable | | | | |
| Other current liabilities | 403,990,704.82 | | | |
| Long-term liabilities | | | | |
| Long-term debt | | | | |
| Other long-term liabilities | | | | |
| Deferred income | | | | |
| Other long-term liabilities | | | | |
| Other long-term liabilities | 117,087,892.28 | | | |
| Other long-term liabilities | 127,715,875.39 | | | |
| Other long-term liabilities | 398,847,341.16 | | | |
| Other long-term liabilities | | | | |
| Other long-term liabilities | 122,690,265.17 | | | |
| Other long-term liabilities | | | | |
| Other long-term liabilities | | | | |
| Other long-term liabilities | | | | |
| Other long-term liabilities | | | | |
| Other long-term liabilities | 1,880,754,618.38 | | | |

| Items | September 30, 2023 | January 1, 2023 | Adjustments | December 31, 2022 |
|--|--------------------|-----------------|-------------|-------------------|
| Accounts receivable | | | | |
| Accounts payable | 4,997,191,595.42 | | | |
| Non-current liabilities: | | | | |
| Long-term debt | | | | |
| Deferred tax liabilities | 2,116,802,507.02 | | | |
| Other non-current liabilities | | | | |
| Other non-current liabilities | | | | |
| Other non-current liabilities | | | | |
| Other non-current liabilities | 92,624,776.83 | | | |
| Other non-current liabilities | 395,725.24 | | | |
| Other non-current liabilities | 40,293,108.90 | | | |
| Other non-current liabilities | 9,876,817.34 | | | |
| Other non-current liabilities | 29,751,781.75 | | | |
| Other non-current liabilities | 334,582,068.96 | | | |
| Other non-current liabilities | | | | |
| Other non-current liabilities | 2,624,326,786.04 | | | |
| Other non-current liabilities | 7,621,518,381.46 | | | |
| Owners' equity: | | | | |
| Common stock | 1,467,296,204.00 | | | |
| Retained earnings | | | | |
| Accumulated other comprehensive income | | | | |
| Other equity | | | | |
| Other equity | 5,854,583,773.47 | | | |
| Other equity | | | | |
| Other equity | 226,528,230.35 | | | |

| Items | September 30, 2023 | January 1, 2023 | Adjustments | December 31, 2022 |
|-------|--------------------|-----------------|-------------|-------------------|
| | | | | |
| | 545,376,458.31 | | | |
| | | | | |
| | 4,312,374,190.99 | | | |
| | 12,406,158,857.12 | | | |
| | 92,883,772.89 | | | |
| | 12,499,042,630.01 | | | |
| | 20,120,561,011.47 | | | |

(3) Audit Report

[The text in this section is extremely faint and illegible, appearing to be a standard audit report header and introductory paragraph.]